Harbour BioMed Enters into Collaboration with Insilico Medicine for Antibody Discovery and Development
Friday, February 21, 2025
Harbour BioMed has entered a strategic collaboration with Insilico Medicine.
The partnership aims to accelerate the development of innovative therapeutic antibodies by combining expertise in AI technology and antibody research.
Under the agreement, Harbour BioMed will integrate its proprietary technology platform, extensive dataset, and experience in antibody development with Insilico Medicine’s advanced AI-driven drug discovery capabilities.
The collaboration will focus on AI-powered antibody applications and early-stage drug discovery programmes targeting novel antibodies. These initiatives will support the development of new treatments for immunology, oncology, and neuroscience.
Harbour BioMed has established a strong presence in antibody discovery, using its Harbour Mice® platform to generate fully human monoclonal antibodies. This technology allows for the production of conventional (H2L2) and heavy chain-only (HCAb) antibodies without additional engineering or humanisation.
The HCAb technology, in particular, produces antibodies that are smaller than traditional IgGs, offering potential advantages for next-generation therapies. The company’s platform has contributed to more than 250 drug discovery projects across different therapeutic areas.
Insilico Medicine has demonstrated its AI platform’s ability to reduce costs and improve efficiency in early-stage drug discovery. Since 2021, the company has developed a pipeline of 30 AI-powered drug assets, with 10 receiving investigational new drug (IND) clearance.
In July 2024, it launched Generative Biologics, an AI-driven tool designed to accelerate the development of novel biologics.
The collaboration will integrate AI technologies with Harbour BioMed’s established platform to streamline antibody discovery and improve candidate selection.
By combining AI-driven approaches with laboratory validation, the partnership aims to develop more efficient methods for identifying and engineering antibodies.
The initiative seeks to advance antibody research and deliver new therapies to address unmet medical needs.
Source: harbourbiomed.com
